Kestra Private Wealth Services LLC Acquires 8,322 Shares of Pfizer Inc. (NYSE:PFE)

Kestra Private Wealth Services LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 3.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 290,204 shares of the biopharmaceutical company’s stock after buying an additional 8,322 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Pfizer were worth $8,355,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Adage Capital Partners GP L.L.C. lifted its stake in Pfizer by 40.5% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock worth $157,215,000 after purchasing an additional 1,365,295 shares in the last quarter. LifePlan Financial LLC purchased a new stake in Pfizer in the 4th quarter worth $255,000. Brookstone Capital Management lifted its stake in Pfizer by 88.5% in the 3rd quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock worth $14,109,000 after purchasing an additional 212,369 shares in the last quarter. ETF Store Inc. lifted its stake in Pfizer by 12.0% in the 3rd quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock worth $214,000 after purchasing an additional 727 shares in the last quarter. Finally, KLCM Advisors Inc. raised its position in shares of Pfizer by 75.0% during the 4th quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after buying an additional 74,487 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.2 %

Shares of NYSE PFE traded up $0.05 during midday trading on Tuesday, reaching $25.69. 13,712,527 shares of the company’s stock traded hands, compared to its average volume of 41,659,465. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The stock’s 50 day simple moving average is $26.92 and its 200-day simple moving average is $28.31. Pfizer Inc. has a one year low of $25.20 and a one year high of $40.37. The company has a market cap of $145.47 billion, a price-to-earnings ratio of 71.50, a P/E/G ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same period last year, the firm earned $1.14 earnings per share. The company’s quarterly revenue was down 41.3% on a year-over-year basis. On average, analysts predict that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 6.54%. Pfizer’s payout ratio is 466.67%.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on PFE shares. Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday, April 15th. Finally, TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a report on Thursday, January 4th. Eleven investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $36.33.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.